Results 101 to 110 of about 1,460,022 (262)

Cluster randomised controlled trial of training practices in reattribution for medically unexplained symptoms [PDF]

open access: yes, 2007
Background: Reattribution is frequently taught to general practitioners (GPs) as a structured consultation that provides a psychological explanation for medically unexplained symptoms. Aims: To determine if practice-based training of GPs in reattribution
Dunn, Graham   +11 more
core   +1 more source

Opsoclonus in Pediatric Patients: Differential Diagnosis and a Practical Approach to Evaluation

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Opsoclonus is an ocular dyskinesia characterized by involuntary, arrhythmic, multidirectional saccades. In pediatrics, opsoclonus is most commonly attributed to the rare neuroinflammatory disorder opsoclonus‐myoclonus‐ataxia syndrome (OMAS), typically considered a paraneoplastic syndrome associated with neural crest tumors. However, opsoclonus
Aubrey C. Reed   +5 more
wiley   +1 more source

Developmental Influences on Medically Unexplained Symptoms [PDF]

open access: yesPsychotherapy and Psychosomatics, 2009
<i>Background:</i> Medically unexplained (or ‘functional’) symptoms (MUS) are physical symptoms that prompt the sufferer to seek healthcare but remain unexplained after an appropriate medical evaluation. Examples of MUS also occur in veterinary medicine.
openaire   +2 more sources

Fifteen-minute consultation: Medically unexplained symptoms

open access: yes, 2016
Medically unexplained symptoms are common and not always easy to manage. A wide range of symptoms may be presented and anxiety in the child, family and paediatrician about the possibility of a missed serious organic diagnosis may hamper effective ...
Cottrell, DJ
core   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Mindfulness Therapies for Medically Unexplained Somatic Symptoms: A Systematic Review

open access: yesPsikiyatride Güncel Yaklaşımlar, 2019
Mindfulness is a new therapeutic approach. Over the last years, it is found to be effective in treating many psychological and somatic symptoms. Somatic symptom disorder was characterized by chronic, recurring and clinically significant somatic symptoms.
Sevcan Aktaş   +2 more
doaj   +1 more source

Return to work with chronic pain: employers' and employees' views [PDF]

open access: yes, 2013
This conference papers given to the Society of Occupational Medicine's Annual Scientific Meeting discusses tensions and some possible ameliorating activities from our 2013 paper of the same name., published in their journal: Wainwright, E., Wainwright, D.
Wainwright, D   +7 more
core   +1 more source

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz   +5 more
wiley   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts   +8 more
wiley   +1 more source

Medically unexplained symptoms and somatoform disorders: prevalence, course and comorbidity. : An eleven year general population study in Norway. [PDF]

open access: yes, 2007
Somatoform disorders (SDs) according to present classifications (ICD-10/DSM-IV) are characterized by “medically unexplained symptoms” (MUSs), i.e. physical symptoms that cannot be fully explained by any detectable medical condition, substance or alcohol ...
Leiknes, Kari Ann
core   +1 more source

Home - About - Disclaimer - Privacy